Y-mAb­s' long­time CEO steps down abrupt­ly as FDA re­views sec­ond pe­di­atric can­cer drug

Over the past sev­en years, Claus Moller helped steer Y-mAbs Ther­a­peu­tics from a se­cre­tive Dan­ish biotech start­up laser-fo­cused on two pe­di­atric can­cer treat­ments to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER